Marc D Samsky

Dr. Marc D Samsky

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in JACC
Verified
Journal Article
Closed access
MSMarc D Samsky
Marc D Samsky
CPChetan B. Patel
Chetan B. Patel
TDTracy A. DeWald
Tracy A. DeWald
ASAlastair D. Smith
Alastair D. Smith
GFG. Michael Felker
G. Michael Felker
AHAdrian F. Hernandez
Adrian F. Hernandez

3 October 2023 in Circulation
Verified
Journal Article
Closed access
RWRon Waksman
Ron Waksman
MPMohit Pahuja
Mohit Pahuja
SDSean van Diepen
Sean van Diepen
APAlastair G. Proudfoot
Alastair G. Proudfoot
DMDavid Morrow
David Morrow
WAWilliam T. Abraham
William T. Abraham
The Shock Academic Research Consortium is a multi-stakeholder group, including representatives from the US Food and Drug Administration and other government agencies, industry, and payers, convened to develop pragmatic consensus definitions useful for the evaluation of clinical trials enrolling patients with cardiogenic shock, including trials evaluating mechanical circulatory support devices. Several in-person and virtual meetings were convened between 2020 and 2022 to discuss the need for developing the standardized definitions required for evaluation of mechanical circulatory support devices in clinical trials for cardiogenic shock patients. The expert panel identified key concepts and topics by performing literature reviews, including previous clinical trials, while recognizing current challenges and the need to advance evidence-based practice and statistical analysis to support future clinical trials. For each category, a lead (primary) author was assigned to perform a literature search and draft a proposed definition, which was presented to the subgroup. These definitions were further modified after feedback from the expert panel meetings until a consensus was reached. This manuscript summarizes the expert panel recommendations focused on outcome definitions, including efficacy and safety.

1 January 2016 in JACC
Verified
Journal Article
Closed access
TATariq Ahmad
Tariq Ahmad
JKJacob P. Kelly
Jacob P. Kelly
RMRobert W. McGarrah
Robert W. McGarrah
AHAnne S. Hellkamp
Anne S. Hellkamp
MFMona Fiuzat
Mona Fiuzat
WKWilliam E. Kraus
William E. Kraus

1 May 2019 in JAMA Cardiology
Verified
Journal Article
Closed access
PDF file
MSMarc D Samsky
Marc D Samsky
AAAndrew P. Ambrosy
Andrew P. Ambrosy
EYErik Youngson
Erik Youngson
LLLi Liang
Li Liang
PKPadma Kaul
Padma Kaul
FMFinlay McAlister
Finlay McAlister
Importance Over the past decade, reducing 30-day readmission rates has been emphasized in the United States (including via the implementation of the Hospital Readmissions Reduction Program) but not Canada. Objective To examine changes that occurred from April 1, 2005, to December 31, 2015, in the United States and Canada for hospitalization length of stay and 30-day readmission rates of patients with heart failure. Design, Setting, and Participants This cohort study included patients admitted with a primary diagnosis of heart failure to Canadian and US hospitals between April 1, 2005, and December 31, 2015, usingInternational Classification of Diseases, Ninth Revision code 428.xx andTenth Revisioncode I50. The study examined secular trends in length of stay and readmissions in both countries and tested for changes after implementation of the Hospital Readmissions Reduction Program using segmented regression models and the association between length of stay and readmissions using patient-level and hospital-level multivariable logistic regression models. Data analysis was completed from February 2018 to August 2018. Main Outcomes and Measures Thirty-day readmissions. Results Between 2005 and 2015, mean length of stay declined marginally in Canadian hospitals (from a mean [SD] of 7.5 [5.7] to 7.3 [5.6] days;P < .001) but remained stable in US hospitals (mean [SD], 4.9 [3.7] days to 4.9 [3.5] days). Thirty-day readmission rates declined similarly in Canada (from 4088 of 20 758 patients [19.7%] to 3823 of 21 733 patients [17.6%] for all-cause readmissions;P < .001; and from 1743 of 20 758 patients [8.4%] to 1490 of 21 733 patients [6.9%] for heart failure–specific readmissions;P < .001) and the United States (from 21.2% to 18.5% for all-cause readmissions; from 7.6% to 5.7% for heart failure–specific readmissions; bothP < .001). There were small but statistically significant positive correlations between length of stay and 30-day readmissions in both Canada (odds ratio, 1.01 [95% CI, 1.01-1.01]) and the United States (odds ratio, 1.01 [95% CI, 1.01-1.01]). Interrupted time-series analysis comparing readmission rates before and after the Hospital Readmissions Reduction Program implementation revealed no significant difference in either country for all-cause readmission rates before and after October 2012. There was also no change in the slope of the temporal trends; in Canada, all-cause readmissions were decreasing 1.1% per year before implementation and 1.3% after implementation (P = .84 for slope change) compared with 1.6% per year in the United States before implementation and 1.8% per year after October 2012 (P = .60 for slope change). Conclusions and Relevance Both Canada and the United States exhibited similar temporal declines in 30-day all-cause readmissions over the past decade. These findings suggest that the Hospital Readmissions Reduction Program did not appear to be associated with this secular trend or length of stay for heart failure in the United States.

1 January 2015 in JACC: Heart Failure
Verified
Journal Article
Closed access
TATariq Ahmad
Tariq Ahmad
TWTeresa Wang
Teresa Wang
EOEmily C. O'BRien
Emily C. O'BRien
MSMarc D Samsky
Marc D Samsky
JPJohn A. Pura
John A. Pura
CPChetan B. Patel
Chetan B. Patel

28 December 2015 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
MSMarc D Samsky
Marc D Samsky
ADAllison Dunning
Allison Dunning
ADAdam David DeVore
Adam David DeVore
PSPhillip J. Schulte
Phillip J. Schulte
RSRandall C. Starling
Randall C. Starling
AHAdrian F. Hernandez
Adrian F. Hernandez
Aims We aimed to characterize abnormal liver function tests in patients with heart failure (HF), as they are commonly encountered yet poorly defined. Methods and results We used data from ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) to characterize associations with baseline liver function tests (LFTs). Each LFT was analysed as both a continuous and dichotomous variable [normal vs. abnormal; bilirubin >1.0 mg/dL; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >35 mmol/L]. Logistic regression assessed the association of LFTs and 30‐day all‐cause mortality and HF rehospitalization, and Cox proportional hazards assessed the association with 180‐day all‐cause mortality among patients alive at a 30‐day landmark. In ASCEND‐HF, 4228 (59%) had complete admission LFT data. Of these, 42% had abnormal bilirubin, 22% had abnormal ALT, and 30% had abnormal AST. Patients with abnormal LFTs were younger, had lower body mass index, and lower left ventricular ejection fraction. In multivariable models, increased total bilirubin was associated with increased 30‐day mortality or HF rehospitalization [hazard ratio (HR) 1.17 per 1 mg/dL increase, 95% confidence interval (CI) 1.04, 1.32; P = 0.012], but not with an increase in 180‐day mortality (HR 1.10, 95% CI 0.97, 1.25; P = 0.13) per 1 mg/dl increase. Compared with normal bilirubin levels, abnormal bilirubin was associated with increased 30‐day mortality or HF rehospitalization (HR 1.24, 95% CI 1.00, 1.54; P = 0.048) and 180‐day mortality (HR 1.32, 95% CI 1.08, 1.62; P = 0.007). We found no association with AST or ALT and outcomes. Conclusion Greater than 40% of patients hospitalized with acute HF had abnormal LFTs. After multivariable adjustment, only elevated bilirubin was independently associated with worse clinical outcomes and may represent an important prognostic variable.